Immune function testing of human pharmaceuticals: regulatory overshoot?

By van der Laan Jan Willem   van Loveren Henk  

Expert Opinion on Drug Safety, Vol. 4, Iss. 1, 2005-01 ,pp. : 1-5

Informa Healthcare

Access to resources Recommend Favorite

Dichlorvos and Carcinogenicity: A Systematic Approach to a Regulatory Decision

By van Maele-Fabry G.   Laurent C.   Willems J.L.  

Regulatory Toxicology and Pharmacology, Vol. 31, Iss. 1, 2000-02 ,pp. : 13-21

Academic Press

Access to resources Recommend Favorite

An Evaluation of the Possible Carcinogenicity of Bisphenol A to Humans

By Haighton L.A.   Hlywka J.J.   Doull J.   Kroes R.   Lynch B.S.   Munro I.C.  

Regulatory Toxicology and Pharmacology, Vol. 35, Iss. 2, 2002-04 ,pp. : 238-254

Academic Press

Access to resources Recommend Favorite

Post-Approval Changes in Pharmaceuticals: Regulatory Perspectives in Europe

By  

Applied Clinical Research, Clinical Trials and Regulatory Affairs, Vol. 2, Iss. 2, 2015-08 ,pp. : 60-68

Bentham Science Publishers

Access to resources Recommend Favorite

Evaluation of the Carcinogenicity of 1,1-Dichloroethylene (Vinylidene Chloride)

By Roberts S.M.   Jordan K.E.   Warren D.A.   Britt J.K.   James R.C.  

Regulatory Toxicology and Pharmacology, Vol. 35, Iss. 1, 2002-02 ,pp. : 44-55

Elsevier

Access to resources Recommend Favorite